Structure prediction with FAMS for proteins screened critically to autoimmune diseases based upon bioimformatics

Shigeharu Ishida[1] Hideaki Umeyama[2,a)] Mitsuo Iwadate[2,b)] Y-h. Taguchi[1,c),d)]

Abstract: Drug discovery for autoimmune diseases is recently recognized to be an important task. In this study, we try to perform structure prediction of proteins whose gene promoter regions were previous reported to be specifically methelysed or de-methylased commonly for three autoimmune diseases, systemic lupus erythematosus, rheumatoid arthritis, and dermatomyositis. FAMS were employed for this purpose and we can predict three dimensional structure with significantly small enough *P*-values. Most of them are suggested to be self immunology related proteins and will be important drug target candidates. We also found some proteins which form complex with each other. The possibility of a new drug target, i.e., suppression of protein complex formation is suggested.

1. Introduction

Autoimmune diseases are recently recognized as serious symptom. For example, systemic lupus erythematosus (SLE), which is known to be one of systemic autoimmune diseases, most often harms the heart, joints, skin, lungs, blood vessels, liver, kidneys, and nervous system. The cause of this disease is unknown. The lack of basic mechanism of the disease prevents us from generating effective drugs to cure this disease. SLE is the secondly frequent connective tissue disease, while the most frequent one is Rheumatoid Arthritis (RA), which is also known to be one of autoimmune diseases. Although there are some proposals about the cause of RA, it has not yet been fully understood. In RA, the arthritis of joints known as synovitis is inflammation of the synovial membrane that lines joints and tendon sheaths. Joints become swollen, tender and warm, and stiffness limits their movement. Another example of autoimmune disease is dermatomyositis (DM), which is also a connective-tissue disease related to polymyositis that is characterized by inflammation of the muscles and the skin. Its cause is unknown, too.

In spite of the lack of basic understanding of diseases' causes, there is a general belief; there should be a common cause of autoimmune diseases. Following this line, in accordance with the recent development of genome science, several conjectures are proposed. For example, O'Hanlon *et al* recently showed that there are common pathways which contribute to multiple systematic autoimmune diseases [1], based upon gene expression analysis. More recently, they have confirmed their findings using proteomic analysis [2]. However, Zhou *et al* [3] found that unaffected monozygotic (MZ) twins share fibroblast gene expression with systemic sclerosis (SSc) patients (counter parts). SSc is also believed to be related to autoimmune diseases. On the other hand, Gervin *et al* [4] recently found that combined analysis between gene expression and methylation enables them to detect slight difference between affected and unaffected twins. Their findings are not contradict to the study by Javierre *et al* [5] who could not find any shared methylation patterns among multiple autoimmune diseases. Thus, at the moment, it is a little bit confusing what kind of aspects can be shared with multiple autoimmune diseases.

A few years ago, we reanalyzed [6] Javierre *et al*'s data [5] using principal component analysis (PCA) and found that some genes' methylation are commonly and significantly different from healthy controls. In this paper, we try to validate our findings using Full Automatic Modeling System (FAMS), which is protein structure prediction server. Using FAMS[7], we can predict functionality of genes by comparing them with the proteins whose function and structure are known. We also validate if these genes can form complex and find many candidates to form protein complex. The possibility that they can be a drug target will be discussed.

2. Materials and Methods

2.1 Selection of candidate genes

Although details are reported previously[6], here we briefly describe how we have selected candidate genes. Javierre *et al* [5] measured promoter methylation patterns using microarray technology (Illumina GoldenGate Methylation Cancer Panel I) for SLE, RA, and DM. Their expression patterns are de-

[1] Department of Physics, Chuo University, Tokyo 112–8551, Japan
[2] Department of Biological Sciences, Chuo University, Tokyo 112–8551, Japan
[a)] umeyama@bio.chuo-u.ac.jp
[b)] iwadate@bio.chuo-u.ac.jp
[c)] tag@granular.com
[d)] Corresponding Author



Fig. 1 Comparison between reference protein AIM2 and model protein 2OQ0_B.

posited to Gene Expression Omnibus with the accession number of GSE19033. We downloaded series_matrix.txt from there, applied PCA to them and picked up gene whose promoters' methylation is significantly different from healthy controls.

2.2 Structure prediction of selected genes

Selected genes' amino acid sequences are downloaded from SWISS Prot. Then their protein structures are inferred by FAMS.

2.3 Protein complex formation prediction

We checked if a pair of model proteins used for structure prediction can form protein complex or not as follows. First, PDB files which contains at least one model protein as a member of protein complex are downloaded. Then, which model proteins are included into the common PDB files is investigated. Thirdly, inter-atomic distances between pairs of model proteins which belong to the same PDB file are computed. If there are at least a pair of atoms whose distances are less than 3.5 Å, a pair of model proteins is listed as a candidate to form protein complex.

3. Results

3.1 Biological significance figured out by FAMS

In Table 1, we have listed genes (i.e., reference proteins) selected by PCA[6], together with the model proteins which are inferred to have similar structure to each of them by FAMS. First of all, FAMS has successfully listed model proteins for most of reference proteins with very small *P*-values. Fig. 1 shows a typical example of model proteins. It is the model protein 2OQ0_B for the reference protein AIM2. Alignment regions are 192 amino acid sequence from total length of 209 amino acid of 2OQ0_B and 191 amino acid sequence from total length 343 amino acid sequence of AIM2. Sequence similarity between two alignment regions is 44 %. *P*-value attributed is 4×10^{-92}. Although this is only one example of typical relationship between model/reference proteins, generally we could get this quality of structural similarities. This means structural homology between models and references is reliable. In addition to this, biological features attributed to the model proteins are often reasonable. Due to the limitation of the space, we cannot explain all of them one by one, we will point out some of these examples.

TRIP6 is expected to have similar structure to CRP1, which is inferred as immune response[8]. TM7SF3 is recognized as cytochrome c oxidase, which was reported to bind to immune gamma-globulins [9]. TIE1, PECAM1 and CSF3R are recognized as DOWN SYNDROME CELL ADHESION MOLECULE (DSCAM), which is known to be immunoglobulin (Ig)-superfamily receptor in insect[10]. SYK is recognzed as TYROSINE-PROTEIN KINASE ZAP-70 and both SYK and ZAP-70 are reported to display distinct requirements for Src family kinases in immune response receptor signal transduction[11]. STAT5A itself is found in PDB, which is reported to play critical role for cytokine responses and normal immune function[12]. SPI1 is recognized as ETS1, which is known to be expressive in SLE and play some function in immune system[13]. S100-A2 itself is in PDB and is reported to be antibodies and inhibitors directed toward receptor for advanced glycation end products (RAGE) ligands[14]. RARA is structurally similar to RXR-α, which is reported to be involved in inflammatory responses[15]. PI3 is as WAP, which is reported to play a role in innate immune[16]. PADI4 is itself in PDB and is reported to be important in RA[17]. MPL's structure is inferred to be similar to IL6RB. IL6R is reported to be a key mediator of RA[18]. LCN2, which is also called as NGAL, is in PDB. NGAL is tried to be used as a marker of inflammatory status for allowing an early diagnosis of inflammatory disease such as autoimmune disease in DS patients[19]. One of HOXB2's model proteins is HNF-6, which is known to cause immunologically distinct feature[20]. AIM2 is structurally similar to IFI16. AIM2 and IFI16 are reported to play critucal role in immunology [21]. CARD15 is inferred to be similar to TLR4 which play a role in cell antiviral response together with TLR3: TICAM1-specific signaling pathways[22]. CD82 is known to be ACETYLCHOLINE RECEPTOR PROTEIN which often play a critical role in immune system[23][*1]. CSF1R is assigned to be TITAN, which is known to be involved in to immune response[24]. SPP1 is recognized as ACID PHOSPHATASE, which is known to be related to be autoimmune prostatitis[25]. LMO2, which is also known to be RHOMBOTIN-2, is known to be related to ZFAT (a zinc-finger gene in autoimmune thyroid disease susceptibility region / an immune-related transcriptional regulator containing 18 C2H2-type zinc-finger domains and one AT-hook)[26]. DHCR24 is regarded as CYTOKININ DEHYDROGENASE. Cytokine has, not to mention, been used to refer to the immunomodulating agents. SEPT9 is homologous to SEPTIN-2, which is reported to be upregulated in cytoskeletal and immune function-related proteome profiles [27]. IFNGR2 is regarded as FIBRONECTIN, which play a role in immune responses in organ transplant recipients[28]. CSF3 itself is in PDB, which is known to have relationship with immune system [29]. GRB7

[*1] Although *P*-value attributed to CD82 is not small enough, reliability of this assignment turns out to be reasonable after some more details consideration (not shown here)

is also recognized as GRB10, which play an important role in immune system, although it is in cancer[30]. HGF is related to COAGULATION FACTOR XI, which is known to be related to immunology[31]. LTB4R is recognized as SUBSTANCE-P RECEPTOR, which is know to have immune response to respiratory syncytial virus infection [32].

These are only a part of immune system related features which are attributed to each gene by FAMS. Although more examples can easily be listed, we omit the rest of them because of length limitation. Anyway, it is clear that FAMS based feature attribution works very well for genes selected by PCA[6].

3.2 Possibility of drug discovery

Although it is interesting enough to find that FAMS can be used for the validation of genes selected by other bioinformatic method, it will be better if we can make use of FAMS for the drug discovery.

3.2.1 Ligand binding to ”pocket”

The most popular method to find drug is to find a small molecule to bind a ”pocket” of each protein. If FAMS can find or suggest such a candidate for each of genes in Table 1, it will be very useful.

For example, there are two proteins, MMP8 and MMP14, in Table 1. They are known to coregulate target genes[33]. Both of them are recognized as members of matrix metalloproteinase (MMP) family, which is inflammation related protein family. For MMP8, using 1XUC_A, which is MMP-13, as a template, FAMS successfully showed that there may bs many ligands to bind MMP8 (Fig. 2). Similarly, for MMP14, using 1BQO_B, which is MMP-3, as a template, FAMS successfully showed that there are many ligands to bind MMP14, too (Fig. 3). Although it is not a finding of a new drug, this shows the potential for proteins listed in Table 1 which can be new drug targets. Further researches following this line will be waited.

3.2.2 Termination of protein complex formation

Other and new possibility of drug target is interruption in protein complex formation. Many proteins cannot work as a single substance but can work only with forming protein complex with other proteins. Thus, if we interrupt the protein complex formation, we can also interrupt the function of protein complex. In Table 2, we have listed protein complex candidates inferred by FAMS. Since FAMS uses a representative protein within each cluster having more than 95 % sequence similarity as a model protein, there are sometimes more than a thousand model proteins which can bind to other proteins. We can immediately recognize that the list includes many reasonable outcomes. For example, there are 52 model proteins listed between CSF3 and CSF3R. By name, it is rather obvious that they are possibly ligand and its receptor. On the other hand, there are 186 model proteins between CSF3R and CSF1R. This represents the possibility that each monomer can form functional protein which can function together, possibly as a receptor. In addition to this, both CSF3R and CSF1R most frequently have non-zero model proteins to bind to each of other reference proteins. It is reasonable since many can bind to them as ligand or can form a receptor together. Close look at this table will give us fruitful information resources to find drug target by the termination of the formation of protein complex.



Fig. 2 Ligand binding to MMP8. Blue and red are reference and model proteins. Green ones are ligand target molecules.

In addition to these known and expected protein complex formation, there are many new findings of protein complex formation candidates. Fig. 4 shows one of such possible candidates. In Table 2, there are 410 possible candidate pairs between CSF1R and PECAM1. Among these, there is one pair having 61 atom pairs contacting with each other. This means, there is a structure on PDB (2ZJS) which includes monomers whose protein structures are expected to be similar to CSF1R and PECAM1, respectively. 2ZJS is SecYE translocon, which are expected to function as a protein-conducting channel[34]. Although this protein complex was found in *Thermus thermophilus*, since this kind of proteins are expected to be highly conserved, it is highly possible that CSF1R and PECAM1 form protein complex which is secreted across or integrated into membranes and play critical role in autoimmune diseases. Thus if we can find the drug which terminates the protein complex formation between CSF1R and PECAM1, it may cure autoimmune diseases.

Although there are many more protein complex formation candidates detected, we cannot report here all of them because of the limitation of space. This will be reported in some other opportunity.

4. Conclusion

In this study, we have demonstrated that how well FAMS can predict protein structures of candidate genes which may play critical roles in autoimmune diseases. Based upon inferred structure, we can annotate protein functions, infer possible ligand which can bind to proteins, and can find possible pairs of proteins which can form proten complex, which can be possible candidates of drug target. It is confirmed that FAMS can work with other bioinformatic predictions.

Acknowledgments This research is partially supported by KAKENHI 23300357.

Table 1 Selected genes and model protein used for structure prediction. Bold ID of PDB indicates that reference protein itself is detected in PDB.

Reference gene symbol	Model PDB ID	*P*-value	gene symbol
AIM2	2OQ0_B	4×10^{-92}	GAMMA-INTERFERON-INDUCIBLE PROTEIN IFI-16
CARD15	3CIY_B	7×10^{-64}	TOLL-LIKE RECEPTOR 4, VARIABLE LYMPHOCYTE (TLR4)
CD82	2BG9_A	0.46	ACETYLCHOLINE RECEPTOR PROTEIN, ALPHA CHAIN
CSF1R	3B43_A	5×10^{-83}	TITIN
CSF3	**1GNC_A**	2×10^{-66}	GRANULOCYTE COLONY-STIMULATING FACTOR
CSF3R	3DMK_A	1×10^{-71}	DOWN SYNDROME CELL ADHESION MOLECULE (DSCAM)
DHCR24	2Q4W_A	1×10^{-115}	CYTOKININ DEHYDROGENASE 7 (CKO7)
ERCC3	2W74_D	1×10^{-152}	TYPE I RESTRICTION ENZYME ECOR124II R PROTEIN (HSDR)
GRB7	3HK0_B	2×10^{-73}	GROWTH FACTOR RECEPTOR-BOUND PROTEIN 10 (GRB10)
HGF	2F83_A	1×10^{-111}	COAGULATION FACTOR XI
HOXB2	2D5V_A	9×10^{-24}	HEPATOCYTE NUCLEAR FACTOR 6 (HNF-6)
IFNGR2	1FNF_A	1×10^{-37}	FIBRONECTIN
LCN2	**1X71_A**	1×10^{-51}	NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN (NGAL)
LMO2	**2XJY_A**	2×10^{-33}	RHOMBOTIN-2
LTB4R	2KS9_A	2×10^{-83}	SUBSTANCE-P RECEPTOR
MMP14	1SU3_B	1×10^{-160}	INTERSTITIAL COLLAGENASE (MMP-1)
MMP8	1SU3_B	1×10^{-171}	INTERSTITIAL COLLAGENASE (MMP-1)
MPL	3L5H_A	4×10^{-63}	INTERLEUKIN-6 RECEPTOR SUBUNIT BETA (IL6RB)
PAD14	**2DEW_X**	0.0	PROTEIN-ARGININE DEIMINASE TYPE IV
PECAM1	3DMK_A	1×10^{-104}	DOWN SYNDROME CELL ADHESION MOLECULE (DSCAM)
PI3	1TWP_A	2×10^{-19}	WHEY ACIDIC PROTEIN (WAP)
RARA	3DZY_A	4×10^{-95}	RETINOIC ACID RECEPTOR RXR-ALPHA
S100A2	**2RGI_A**	4×10^{-19}	PROTEIN S100-A2
SEPT9	3FTQ_A	1×10^{-137}	SEPTIN-2
SLC22A18	1PW4_A	1×10^{-108}	GLYCEROL-3-PHOSPHATE TRANSPORTER
SPI1	1GVJ_B	1×10^{-21}	C-ETS-1 PROTEIN (ETS1)
SPP1	1D2T_A	3×10^{-14}	ACID PHOSPHATASE (ACP)
STAT5A	**1Y1U_A**	0.0	SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION (STAT5A)
SYK	2OZO_A	1×10^{-168}	TYROSINE-PROTEIN KINASE ZAP-70
TIE1	3DMK_A	2×10^{-84}	DOWN SYNDROME CELL ADHESION MOLECULE (DSCAM)
TM7SF3	[1AR1_A]	6×10^{-88}	CYTOCHROME C OXIDASE
TRIP6	1B8T_A	2×10^{-32}	CYSTEINE-RICH PROTEIN 1 (CRP1)
VAMP8	2KOG_A	1×10^{-21}	VESICLE-ASSOCIATED MEMBRANE PROTEIN 2 (VAMP2)



Fig. 3 Ligand binding to MMP14. Blue and red are reference and model proteins. Green ones are ligand target molecules.



Fig. 4 Protein complex formation candidates between PECAM1 (cyan) and CSF1R (magenta), based upon protein structure of PDB 2ZJS. Blue and red region are excluded from matching between model and reference proteins.

References

[1] O'Hanlon, T. P., Rider, L. G., Gan, L., Fannin, R., Paules, R. S., Umbach, D. M., Weinberg, C. R., Shah, R. R., Mav, D., Gourley, M. F. and Miller, F. W.: Gene expression profiles from discordant monozygotic twins suggest that molecular pathways are shared among multiple systemic autoimmune diseases, *Arthritis Res. Ther.*, Vol. 13, No. 2, p. R69 (2011).

[2] O'Hanlon, T. P., Li, Z., Gan, L., Gourley, M. F., Rider, L. G. and Miller, F. W.: Plasma proteomic profiles from disease-discordant monozygotic twins suggest that molecular pathways are shared in multiple systemic autoimmune diseases*, *Arthritis Res. Ther.*, Vol. 13, No. 6, p. R181 (2011).

[3] Zhou, X., Tan, F. K., Xiong, M., Arnett, F. C. and Feghali-Bostwick, C. A.: Monozygotic twins clinically discordant for scleroderma show concordance for fibroblast gene expression profiles, *Arthritis Rheum.*, Vol. 52, No. 10, pp. 3305–3314 (2005).

[4] Gervin, K., Vigeland, M. D., Mattingsdal, M., Hammer?, M., Nygard, H., Olsen, A. O., Brandt, I., Harris, J. R., Undlien, D. E. and Lyle, R.: DNA methylation and gene expression changes in monozygotic twins

Table 2 The number of model proteins which can bind to other model proteins

	AIM2_P624_F	CARD15_P302_R	CD82_P557_R	CSF1R_E26_F	CSF3_E242_R	CSF3R_P472_F	DHCR24_P652_R	ERCC3_P1210_R	GRB7_E71_R	HGF_E102_R	HOXB2_P99_F	IFNGR2_P377_R	LCN2_P86_R	LMO2_E148_F	LTB4R_P163_F	MMP14_P13_F	MMP8_E89_R	MPL_P62_F	PADI4_E24_F	PECAM1_E32_R	PI3_P274_R	RARA_P1076_R	S100A2_E36_R	SEPT9_P374_F	SLC22A18_P216_R	SPI1_E205_F	SPP1_P647_F	STAT5A_P704_R	SYK_P584_F	TIE1_E66_R	TM7SF3_P1068_R	TRIP6_P1090_F	VAMP8_P241_F
AIM2_P624_F		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CARD15_P302_R	0		0	2	5	0	0	16	0	3	0	0	0	0	0	0	0	0	0	5	0	0	0	0	0	0	0	8	0	0	0	0	0	0
CD82_P557_R	0	0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CSF1R_E26_F	0	2	0		0	186	0	10	0	25	0	5	8	0	0	0	0	0	5	410	0	0	2	0	0	0	0	9	0	1223	0	1355	0	0
CSF3_E242_R	0	0	0	0		52	0	0	0	0	0	42	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	204	0	0
CSF3R_P472_F	0	5	0	186	52		0	0	0	107	0	166	48	0	3	0	0	115	0	1177	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DHCR24_P652_R	0	0	0	0	0	0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ERCC3_P1210_R	0	16	0	0	0	0	0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
GRB7_E71_R	0	0	0	10	0	0	0	0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HGF_E102_R	0	2	0	25	0	107	0	0	0		0	140	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HOXB2_P99_F	0	0	0	0	0	0	0	0	0	0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IFNGR2_P377_R	0	0	0	5	42	166	0	0	0	140	0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
LCN2_P86_R	0	0	0	4	0	24	0	0	0	2	0	0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
LMO2_E148_F	0	0	0	0	0	0	0	0	0	0	0	0	0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
LTB4R_P163_F	0	0	0	0	0	3	0	0	0	0	0	0	0	0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MMP14_P13_F	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		125	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MMP8_E89_R	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	125		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MPL_P62_F	0	0	0	5	28	115	0	0	0	0	0	91	0	0	0	0	0		0	19	0	0	3	0	0	0	0	0	0	0	0	0	0	0	0	0
PADI4_E24_F	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PECAM1_E32_R	0	5	0	410	1	1177	0	0	0	84	0	24	32	0	6	0	0	19	0		0	0	0	0	0	0	0	0	0	1	0	129	0	0	0	0
PI3_P274_R	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	0	0	0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RARA_P1076_R	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3	0	0	0		0	0	0	0	0	0	0	0	0	0	0	0	0	0
S100A2_E36_R	0	0	0	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		0	0	0	0	0	0	1	0	0	0	0	0	0
SEPT9_P374_F	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		0	0	0	0	0	0	0	0	0	0	0	0
SLC22A18_P216_R	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		0	0	0	0	0	0	0	0	0	0	0
SPI1_E205_F	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		0	0	0	0	0	0	0	0	0	0
SPP1_P647_F	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		0	0	0	0	0	0	0	0	0
STAT5A_P704_R	0	8	0	9	0	0	0	170	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	1	0	0	0		164	9	0	0	0	0	0	0
SYK_P584_F	0	0	0	1223	0	0	0	211	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	164		1200	0	0	0	0	0	0
TIE1_E66_R	0	0	0	1355	0	204	0	10	0	0	0	54	0	0	0	0	0	0	0	129	0	0	1	0	0	0	0	9	1200		0	0	0	0	0	0
TM7SF3_P1068_R	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		0	0	0	0	0
TRIP6_P1090_F	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		0	0	0	0
VAMP8_P241_F	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		0	0	0

discordant for psoriasis: identification of epigenetically dysregulated genes, *PLoS Genet.*, Vol. 8, No. 1, p. e1002454 (2012).

[5] Javierre, B. M., Fernandez, A. F., Richter, J., Al-Shahrour, F., Martin-Subero, J. I., Rodriguez-Ubreva, J., Berdasco, M., Fraga, M. F., O'Hanlon, T. P., Rider, L. G., Jacinto, F. V., Lopez-Longo, F. J., Dopazo, J., Forn, M., Peinado, M. A., Carreno, L., Sawalha, A. H., Harley, J. B., Siebert, R., Esteller, M., Miller, F. W. and Ballestar, E.: Changes in the pattern of DNA methylation associate with twin discordance in systemic lupus erythematosus, *Genome Res.*, Vol. 20, No. 2, pp. 170–179 (2010).

[6] Taguchi, Y.-h.: A significance test based upon PCA, *SIG-DMSM*, Vol. A903, pp. 38–47 (2010).

[7] Umeyama, H. and Iwadate, M.: *FAMS and FAMSBASE for Protein Structure*, (online), DOI: 10.1002/0471250953.bi0502s04, John Wiley & Sons, Inc. (2002).

[8] Latonen, L., Jarvinen, P. M., Suomela, S., Moore, H. M., Saarialho-Kere, U. and Laiho, M.: Ultraviolet B radiation regulates cysteine-rich protein 1 in human keratinocytes, *Photodermatol Photoimmunol Photomed*, Vol. 26, No. 2, pp. 70–77 (2010).

[9] Frey, T. G., Chan, S. H. and Schatz, G.: Structure and orientation of cytochrome c oxidase in crystalline membranes. Studies by electron microscopy and by labeling with subunit-specific antibodies, *J. Biol. Chem.*, Vol. 253, No. 12, pp. 4389–4395 (1978).

[10] Watson, F. L., Puttmann-Holgado, R., Thomas, F., Lamar, D. L., Hughes, M., Kondo, M., Rebel, V. I. and Schmucker, D.: Extensive diversity of Ig-superfamily proteins in the immune system of insects, *Science*, Vol. 309, No. 5742, pp. 1874–1878 (2005).

[11] Zoller, K. E., MacNeil, I. A. and Brugge, J. S.: Protein tyrosine kinases Syk and ZAP-70 display distinct requirements for Src family kinases in immune response receptor signal transduction, *J. Immunol.*, Vol. 158, No. 4, pp. 1650–1659 (1997).

[12] Lin, J. X., Li, P., Liu, D., Jin, H. T., He, J., Rasheed, M. A., Rochman, Y., Wang, L., Cui, K., Liu, C., Kelsall, B. L., Ahmed, R. and Leonard, W. J.: Critical Role of STAT5 Transcription Factor Tetramerization for Cytokine Responses and Normal Immune Function, *Immunity*, Vol. 36, No. 4, pp. 586–599 (2012).

[13] Pan, H. F., Leng, R. X., Tao, J. H., Li, X. P. and Ye, D. Q.: Ets-1: a new player in the pathogenesis of systemic lupus erythematosus?, *Lupus*, Vol. 20, No. 3, pp. 227–230 (2011).

[14] Heijmans, J., Buller, N. V., Hoff, E., Dihal, A. A., van der Poll, T., van Zoelen, M. A., Bierhaus, A., Biemond, I., Hardwick, J. C., Hommes, D. W., Muncan, V. and van den Brink, G. R.: Rage signalling promotes intestinal tumourigenesis, *Oncogene* (2012).

[15] Selvaraj, R. K., Shanmugasundaram, R. and Klasing, K. C.: Effects of dietary lutein and PUFA on PPAR and RXR isomer expression in chickens during an inflammatory response, *Comp. Biochem. Physiol., Part A Mol. Integr. Physiol.*, Vol. 157, No. 3, pp. 198–203 (2010).

[16] Bingle, C. D. and Vyakarnam, A.: Novel innate immune functions of the whey acidic protein family, *Trends Immunol.*, Vol. 29, No. 9, pp. 444–453 (2008).

[17] Abd-Allah, S. H., el Shal, A. S., Shalaby, S. M., Pasha, H. F., Abou el Saoud, A. M., el Najjar, A. R. and el Shahawy, E. E.: PADI4 polymorphisms and related haplotype in rheumatoid arthritis patients, *Joint Bone Spine*, Vol. 79, No. 2, pp. 124–128 (2012).

[18] Cronstein, B. N.: Interleukin-6–a key mediator of systemic and local symptoms in rheumatoid arthritis, *Bull NYU Hosp Jt Dis*, Vol. 65 Suppl 1, pp. S11–15 (2007).

[19] Dogliotti, G., Galliera, E., Licastro, F., Porcellini, E. and Corsi, M. M.: Serum neutrophil gelatinase-B associated lipocalin (NGAL) levels in Down's syndrome patients, *Immun Ageing*, Vol. 7 Suppl 1, p. S7 (2010).

[20] Samadani, U. and Costa, R. H.: The transcriptional activator hepatocyte nuclear factor 6 regulates liver gene expression, *Mol. Cell. Biol.*, Vol. 16, No. 11, pp. 6273–6284 (1996).

[21] Jin, T., Perry, A., Jiang, J., Smith, P., Curry, J. A., Unterholzner, L., Jiang, Z., Horvath, G., Rathinam, V. A., Johnstone, R. W., Hornung, V., Latz, E., Bowie, A. G., Fitzgerald, K. A. and Xiao, T. S.: Structures of the HIN Domain:DNA Complexes Reveal Ligand Binding and Activation Mechanisms of the AIM2 Inflammasome and IFI16 Receptor, *Immunity*, Vol. 36, No. 4, pp. 561–571 (2012).

[22] Meylan, E., Burns, K., Hofmann, K., Blancheteau, V., Martinon, F., Kelliher, M. and Tschopp, J.: RIP1 is an essential mediator of Toll-like receptor 3-induced NF-kappa B activation, *Nat. Immunol.*, Vol. 5, No. 5, pp. 503–507 (2004).

[23] Quek, A. M., Britton, J. W., McKeon, A., So, E., Lennon, V. A., Shin, C., Klein, C. J., Watson, R. E., Kotsenas, A. L., Lagerlund, T. D., Cascino, G. D., Worrell, G. A., Wirrell, E. C., Nickels, K. C., Aksamit, A. J., Noe, K. H. and Pittock, S. J.: Autoimmune Epilepsy: Clinical Characteristics and Response to Immunotherapy, *Arch Neurol*, Vol. 69, No. 5, pp. 582–593 (2012).

[24] Skeie, G. O., Bentsen, P. T., Freiburg, A., Aarli, J. A. and Gilhus, N. E.: Cell-mediated immune response against titin in myasthenia gravis: evidence for the involvement of Th1 and Th2 cells, *Scand. J. Immunol.*, Vol. 47, No. 1, pp. 76–81 (1998).

[25] Fong, L., Ruegg, C. L., Brockstedt, D., Engleman, E. G. and Laus, R.: Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization: implications for immunotherapy of prostate cancer, *J. Immunol.*, Vol. 159, No. 7, pp. 3113–3117 (1997).

[26] Tsunoda, T., Takashima, Y., Tanaka, Y., Fujimoto, T., Doi, K., Hirose, Y., Koyanagi, M., Yoshida, Y., Okamura, T., Kuroki, M., Sasazuki, T. and Shirasawa, S.: Immune-related zinc finger gene ZFAT is an essential transcriptional regulator for hematopoietic differentiation in blood islands, *Proc. Natl. Acad. Sci. U.S.A.*, Vol. 107, No. 32, pp. 14199–14204 (2010).

[27] Gabr, A. A., Reed, M., Newman, D. R., Pohl, J., Khosla, J. and Sannes, P. L.: Alterations in cytoskeletal and immune function-related proteome profiles in whole rat lung following intratracheal instillation of heparin, *Respir. Res.*, Vol. 8, p. 36 (2007).

[28] Coito, A. J., de Sousa, M. and Kupiec-Weglinski, J. W.: Fibronectin in immune responses in organ transplant recipients, *Dev. Immunol.*, Vol. 7, No. 2-4, pp. 239–248 (2000).

[29] Sarkar, S., Song, Y., Sarkar, S., Kipen, H. M., Laumbach, R. J., Zhang, J., Strickland, P. A., Gardner, C. R. and Schwander, S.: Suppression of the NF-尊 B pathway by diesel exhaust particles impairs human antimycobacterial immunity, *J. Immunol.*, Vol. 188, No. 6, pp. 2778–2793 (2012).

[30] O-Sullivan, I., Chopra, A., Carr, J., Kim, T. S. and Cohen, E. P.: Immunity to growth factor receptor-bound protein 10, a signal transduction molecule, inhibits the growth of breast cancer in mice, *Cancer Res.*, Vol. 68, No. 7, pp. 2463–2470 (2008).

[31] Bouma, B. N., Vlooswijk, R. A. and Griffin, J. H.: Immunologic studies of human coagulation factor XI and its complex with high molecular weight kininogen, *Blood*, Vol. 62, No. 5, pp. 1123–1131 (1983).

[32] Tripp, R. A., Barskey, A., Goss, L. and Anderson, L. J.: Substance P receptor expression on lymphocytes is associated with the immune response to respiratory syncytial virus infection, *J. Neuroimmunol.*, Vol. 129, No. 1-2, pp. 141–153 (2002).

[33] Silva, J. A., Ferrucci, D. L., Peroni, L. A., Abrahao, P. G., Salamene, A. F., Rossa-Junior, C., Carvalho, H. F. and Stach-Machado, D. R.: Sequential IL-23 and IL-17 and increased Mmp8 and Mmp14 expression characterize the progression of an experimental model of periodontal disease in type 1 diabetes, *J. Cell. Physiol.*, Vol. 227, No. 6, pp. 2441–2450 (2012).

[34] Tsukazaki, T., Mori, H., Fukai, S., Ishitani, R., Mori, T., Dohmae, N., Perederina, A., Sugita, Y., Vassylyev, D. G., Ito, K. and Nureki, O.: Conformational transition of Sec machinery inferred from bacterial SecYE structures, *Nature*, Vol. 455, No. 7215, pp. 988–991 (2008).